Research & Development

Publications

Analysis of Clinical Outcomes in the NODE-301 Trial

0
Etripamil Nasal Spray Relieves Symptoms and Reduces Emergency Room Interventions in Patients with Paroxysmal Supraventricular Tachycardia (PSVT). ACCESS THE FULL TEXT

Trends in Healthcare Resource Use and Expenditures in Patients with Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States. 2021.

2
This study explored the cost of health care spending in patients under the age of 65 three years before and three years after a PSVT diagnosis. ACCESS THE FULL TEXT

Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.

2
This study assesses gender differences in diagnosis, healthcare resource use, expenditures, and treatment. ACCESS THE FULL TEXT

Etripamil Nasal Spray For Acute Termination Of Spontaneous Episodes Of Paroxysmal Supraventricular Tachycardia.

0
ACCESS THE FULL TEXT

Healthcare Resource Use and Expenditures in Patients Newly Diagnosed With Paroxysmal Supraventricular Tachycardia. American Journal of Cardiology. 2020.

2
This study explored the cost of health care spending in the year immediately before and after a PSVT diagnosis, segmenting patients above and under the age of 65. ACCESS THE FULL TEXT

Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. Journal of the American College of Cardiology. 2018.

1
This study reported the results of our NODE-1 phase 2 study on the efficacy and safety of etripamil nasal spray vs. placebo in an at-home setting. ACCESS THE FULL TEXT

Variations in Healthcare Resource Use and Expenditures by Age in Patients under Age 65 Newly Diagnosed with Paroxysmal Supraventricular Tachycardia (PSVT) in the United States

0
ACCESS THE FULL TEXT

Healthcare Resource Use and Costs Following Catheter Ablation in Paroxysmal Supraventricular Tachycardia (PSVT) Patients Age <65

0
ACCESS THE FULL TEXT